Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.
Taylor
David N
DN
Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. david.taylor@vaxinnate.com
McKenzie
Robin
R
Durbin
Anna
A
Carpenter
Colleen
C
Haake
Robert
R
Bourgeois
A Louis
AL
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004405:Dysentery, Bacillary / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000078262:Rifaximin; D012763:Shigella flexneri / Q000187:drug effects* / Q000472:pathogenicity; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D012294:Rifamycins; D000078262:Rifaximin